Clinical Trial Update: Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder

View source ↗

Summary

Patients in the trial are transitioning from Exubera Inhalation Powder to Technosphere Insulin Inhalation Powder (Afrezza). The study is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• Afrezza (Technosphere insulin)
• Exubera Inhalation Powder (insulin inhalation powder)

Snippet

Sponsor: Mannkind Corporation | Conditions: Type 1 Diabetes, Type 2 Diabetes | Status: NO_LONGER_AVAILABLE